What's new concerning the chemobrain?;Qu'en-est-il du chemobrain?

Revue Neurologique

Volumn 169, Issue 3, 2013, Pages 216-222

  Taillia, H ^a  

^a University of Paris Descartes   (France)

Author keywords

Cancer; Chemobrain; Chemotherapy; Cognition; Neuropsychology

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; AWARENESS; CANCER CHEMOTHERAPY; CHEMOBRAIN; CLINICAL PRACTICE; COGNITIVE DEFECT; FRANCE; HUMAN; MEDICAL EXPERT; NEOPLASM; PRACTICE GUIDELINE; STATISTICAL ANALYSIS;

EID: 84875249764     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2012.06.020     Document Type: Review

References (47)

1. T.A. Ahles, and A.J. Saykin Cognitive effects of standard-dose chemotherapy in patients with cancer Cancer Invest 19 2001 812 820
2. T.A. Ahles, and A.J. Saykin Candidate mechanisms for chemotherapy-induced cognitive changes Nature Rev Cancer 7 2007 192 201
3. T.A. Ahles, A.J. Saykin, C.T. Furstenberg, B. Cole, L.A. Mott, and K. Skalla Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma J Clin Oncol 20 2002 485 493
4. T.A. Ahles, A.J. Saykin, B.C. McDonald, C.T. Furstenberg, B.F. Cole, and B.S. Hanscom Cognitive function in breast cancer patients prior to adjuvant treatment Breast Cancer Res Treat 110 2008 143 152
5. T.A. Ahles, A.J. Saykin, B.C. McDonald, Y. Li, C.T. Furstenberg, and B.S. Hanscom Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve J Clin Oncol 20 2010 4434 4440
6. T.A. Ahles, A.J. Saykin, W.W. Noll, C.T. Furstenberg, S. Guerin, and B. Cole The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard-dose chemotherapy Psychooncology 12 2003 612 619
7. C.D. Aluise, S. Miriyala, T. Noel, R. Sultana, P. Junsuwadee, and T.J. Taylor 2-mercaptoethanesulfonate (MESNA) prevents doxorubicin (Dox)-induced plasma protein oxidation and TNFα release: implications for the reactive oxygen species-mediated mechanisms of chemobrain Free Radic Biol Med 50 2011 1630 1638
8. A.A. Argyriou, K. Assimakopoulos, G. Iconomou, F. Giannakopoulou, and H. Kalofonos Either called "chemobrain" or "chemo-fog", the long-term chemotherapy-induced cognitive in cancer survivors is real J Pain Symptom Manage 41 2011 126 139
9. N. Biglia, G. Moggio, E. Peano, P. Sgandurra, R. Ponzone, and R.E. Nappi Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions and body weigh J Sex Med 7 2010 1891 1900
10. N. Boykoff, M. Moieni, and S.K. Subramanian Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response J Cancer Surviv 3 2009 223 232
11. S.A. Castellon, P.A. Ganz, J.E. Bower, L. Petersen, L. Abraham, and G.A. Greendale Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen J Clin Exp Neuropsychol 26 2004 955 969
12. D.D. Correa, Q. Zhou, H.T. Thaler, M. Maziaz, K. Hurley, and M.L. Hensley Cognitive functions in long-term survivors of ovarian cancer Gynecol Oncol 119 2010 66 69
13. J. Dietrich, R. Han, Y. Yang, M. Mayer-Proschel, and M. Noble CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo J Biol 5 2006 22
14. R.J. Ferguson, A.G. Cassel, and R.F.S. Dawson Cognitive effects of cancer chemotherapy in adult cancer survivors: cognitive-behavioral management J Rat-Emo Cognitive-Behav Ther 28 2010 25 41
15. M.I. Fitch, J. Armstrong, and S. Tsang Patients' experiences with cognitive changes after chemotherapy Can Oncol Nurs J 18 2008 180 192
16. K. Hermelink, V. Henschel, M. Untch, I. Bauerfeind, M.P. Lux, and K. Munzel Short-term effects of treatment-induced hormonal changes on cognition function in breast cancer patients Cancer 113 2008 2431 2439
17. K. Hermelink, H. Kuchenhoff, M. Untch, I. Bauerfeind, M.P. Lux, and M. Buhner Two differents sides of "chemobrain": determinants and non-determinants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study Psychooncology 19 2010 1321 1328
18. A. Hurria, G. Somlo, and T. Ahles Renaming "chemobrain" Cancer Invest 25 2007 373 377
19. C.E. Jansen, C. Miaskowski, M. Dodd, G. Dowling, and J. Kramer A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function Cancer 104 2005 2222 2233
20. V. Jenkins, V. Shilling, G. Deutsch, D. Bloomfield, R. Morris, and H. Allan Bishop A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer Br J Cancer 94 2006 828 834
21. G. Joshi, C.D. Aluise, M.P. Cole, R. Sultana, W.M. Pierce, and M. Core Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycine: implications for oxidative stress-mediated chemobrain Neuroscience 166 2010 796 807
22. G.D. Lee, D.L. Jongo, Y. Wang, J.M. Rifkind, L. Abdul-Raman, and J.A. Mamczarz Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy Clin Cancer Res 12 2006 198 205
23. J.E. Mac Leod, J.A. Deleo, W.F. Hickey, T.A. Ahles, A.J. Saykin, and D.J. Bucci Cancer chemotherapy impairs contextual but not cue-specific fear memory Behav Brain Res 181 2007 168 172
24. H. Mar Fan, A. Park, W. Xu, Q.L. Yi, S. Braganza, and J. Chang The influence of erythropietin on cognitive function in women following chemotherapy for breast cancer Psychooncology 18 2009 156 161
25. T. Matsuda, T. Takayama, M. Tashiro, Y. Nakamura, Y. Ohashi, and A.K. Shimozum Mild cognitive impairment after adjuvant chemotherapy in the breast cancer patients: evaluation of appropriate research design and methodology to measure symptoms Breast Cancer 12 2005 279 287
26. M. Mehlsen, A. Pedersen, A. Jensen, and R. Zachariae No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy Psychooncology 18 2009 248 257
27. T. Mitchell, and P. Turton "Chemobrain": concentration and memory effects in people receiving chemotherapy-a descriptive phenomenological study Eur J Cancer Care (Engl) 20 2011 539 548
28. S. Mustafa, A. Walker, G. Bennett, and P.M. Wigmore 5 fluoro-uracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus Eur J Neurosci 28 2008 323 330
29. J.S. Myers Chemotherapy-related cognitive impairment Clin J Oncol Nurs 13 2009 413 421
30. A.B. Reiriz, G.K. Reolon, T. Preissler, J.O. Rosado, J.A. Henriques, and R. Roesler Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice Clin Cancer Res 12 2006 5000
31. D. Ricard, H. Taillia, and J.L. Renard Brain damage from anti-cancer treatments in adults Curr Opin Oncol 21 2009 559 565
32. S.B. Schagen, F.S. Van Dam, M.J. Muller, W. Boogerd, J. Lindeboom, and P.F. Bruning Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma Cancer 85 1999 640 650
33. V. Shilling, V. Jenkins, and I.S. Trapala The (mis)classification of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy Breast Cancer Res Treat 95 2006 125 129
34. D.H. Silverman, C.J. Dy, S.A. Castellon, J. Lai, B.S. Pio, and L. Abraham Altered frontocortical, cerebellar and basal ganglia activity in adjuvant-treated breast survivors 5-10 years after chemotherapy Breast Cancer Res Treat 103 2007 303 311
35. E. Steffen-Smith, P. Wolters, P. Albert, E. Baker, K. Shimoda, and A. Barnett Detection and characterization of neurotoxicitiy in cancer patients using proton MR spectroscopy Childs Nerv Syst 24 2008 807 813
36. A. Stewart, B. Colins, J. Mackenzie, E. Tomiak, S. Verma, and C. Bielejew The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study Psychooncology 23 2007 122 130
37. S. Taillibert, D. Voillery, and C. Bernard-Marty Chemobrain: is systemic chemotherapy neurotoxic? Curr Opin Oncol 19 2007 623 627
38. J. Tangpong, M.P. Cole, R. Sultana, G. Joshi, S. Estus, and M. Vore Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity Neurobiol Dis 23 2006 127 139
39. J. Tangpong, M.P. Cole, R. Sultana, S. Estus, M. Vore, and W. Saint Clair Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain J Neurochem 100 2007 191 200
40. F.S. Van Dam, S.B. Schagen, M.J. Muller, W. Boogerd, E. VandeWall, and M.E. Droogleever Fortuyn Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy J Natl Cancer Inst 90 1998 210 218
41. J.L. Vardy, H. Dhillon, W. Xu, A. Dodd, A. Park, and S.B. Rourke Cognitive function and fatigue in colorectal cancer (CRC) patients: baseline assessments prior to chemotherapy J Clin Oncol 27 15S 2009 9557
42. J.L. Vardy, J.S. Wefel, T. Ahles, I.F. Tannock, and S.B. Schagen Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop Ann Oncol 19 2008 623 626
43. J.S. Wefel, R. Lenzi, R. Theriault, A.U. Buzdar, S. Cruickshank, and C.A. Meyers "Chemobrain" in breast carcinoma? A prologue Cancer 101 2004 466 475
44. J.S. Wefel, J. Vardy, T. Ahles, and S.B. Schagen International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer Lancet Oncol 12 2011 703 708
45. B. Weiss Chemobrain: a translational challenge for neurotoxicology Neurotoxicology 29 2008 891 898
46. K.A. Whitney, P.H. Lysaker, A.R. Steiner, J.N. Hook, D.D. Estes, and N.H. Hanna Is "chemobrain" a transient state? A prospective pilot study among persons with non-small cell lung cancer J Support Oncol 6 2008 313 321
47. M.H. Wieneke, and E.R. Dienst Neuropsychological assessment of cognitive function following chemotherapy for breast cancer Psychooncology 4 1995 61 66